| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 33,665 | 33,820 | 18:04 | |
| 33,720 | 33,780 | 18:04 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 34,200 | 15 | |||
| 34,190 | 7.377 | |||
| 34,055 | 4.925 | |||
| 33,930 | 2.516 | |||
| 33,800 | 632 | |||
| 33,795 | 6 | |||
| 33,790 | 160 | |||
| 33,780 | 130 | |||
| 33,770 | 757 | |||
| 33,750 | 1 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/nov.htm [/URL] | ||||
| 250 | 33,705 | |||
| 507 | 33,665 | |||
| 130 | 33,655 | |||
| 240 | 33,650 | |||
| 130 | 33,645 | |||
| 632 | 33,635 | |||
| 2.489 | 33,620 | |||
| 200 | 33,600 | |||
| 4.898 | 33,495 | |||
| 7.079 | 33,375 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 16.555 | 0,998 | 16.519 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:35:37 | 33,725 | 16.802 |
| 17:29:59 | 33,880 | 400 |
| 17:29:03 | 33,900 | 549 |
| 17:29:03 | 33,900 | 66 |
| 17:29:03 | 33,905 | 134 |
| 17:28:38 | 33,910 | 2 |
| 17:28:38 | 33,905 | 160 |
| 17:28:38 | 33,900 | 370 |
| 17:28:31 | 33,895 | 135 |
| 17:28:23 | 33,870 | 741 |
| 17:28:23 | 33,880 | 400 |
| 17:28:01 | 33,900 | 46 |
| 17:28:01 | 33,900 | 44 |
| 17:28:01 | 33,895 | 57 |
| 17:27:49 | 33,890 | 35 |
| 17:26:55 | 33,880 | 259 |
| 17:25:45 | 33,880 | 67 |
| 17:25:45 | 33,880 | 33 |
| 17:25:03 | 33,840 | 83 |
| 17:24:56 | 33,850 | 161 |
| Tagesumsatz Xetra | +0,560 +1,69 % | 261.354 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16:38 | Eilmeldung am Abend: NOVO NORDISK A/S im Fokus! | 6 | Maximilian Berger | ||
| NOVO NORDISK Aktie jetzt für 0€ handeln | |||||
| 15:34 | NVO Inks Deal With OpenAI for Speedy Drug Discovery Globally, Stock Up | 15 | Zacks | ||
| 15:18 | GoodRx offers Wegovy HD at $399 monthly for self-pay patients | 19 | Investing.com | ||
| 09:06 | JEFFERIES stuft NOVO NORDISK auf 'Hold' | 633 | dpa-AFX-Analyser | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Novo Nordisk auf "Hold" mit einem Kursziel von 270 dänischen Kronen belassen. Die Nachfragen der US-Zulassungsbehörde FDA... ► Artikel lesen | |
| 08:30 | Novo nordisk ÜBERRASCHT Anleger: Könnte die Aktie jetzt komplett durchstarten? - Das sollten Sie jetzt wissen | Hebelschein-Spekulant |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 13:15 | Dividendenbekanntmachungen (15.04.2026) | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,63 USD 0,5342 EUR ABBOTT LABORATORIES CDR CA0028221046 0,1109 CAD 0,0683 EUR ABBVIE INC US00287Y1091 1... ► Artikel lesen | |
| 13:42 | Tilray Brands, Inc.: Tilray Brands Accelerates Next Phase of Global Growth and Market Leadership | GlobeNewswire (Europe) | NEW YORK and LEAMINGTON, Ontario, April 15, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc.?("Tilray", "our", "we" or the "Company") (NASDAQ: TLRY; TSX: TLRY), a global lifestyle and consumer packaged... ► Artikel lesen | |
| 14:10 | Boehringer Ingelheim Limited: Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3-targeting T-Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | GlobeNewswire (Europe) | Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3-targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).
Phase... ► Artikel lesen | |
| 14:10 | Teva Pharmaceutical Industries Ltd: Teva Launches Home Ground Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners | GlobeNewswire (Europe) | For people living with schizophrenia who may find daily disease management overwhelming due to fragmented support and resources, Home Ground Schizophrenia Community is a centralized destination that... ► Artikel lesen | |
| 13:06 | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications | GlobeNewswire (Europe) | Dr. Dennis K. McBride, PhD (CAPT, Medical Service Corps, US Navy, Ret., Distinguished Research Fellow, National Defense University, and former senior executive, Office Secretary of Defense) to serve... ► Artikel lesen |